Wound dressing for diminishing inflammation, easing pain and promoting wound healing and preparation method thereof

Abstract

The invention provides a wound dressing for diminishing inflammation, easing pain and promoting wound healing and a preparation method thereof. The wound dressing capable of diminishing inflammation, easing pain and promoting wound healing is prepared from the following components in parts by mass: 6 to 10 parts of oxidized sodium alginate, 7 to 9 parts of hydrazide gelatin, 1 to 1.5 parts of tannic acid, 8 to 12 parts of polyethylene glycol, 0.05 to 0.1 part of cannabidiol, 0.05 to 0.1 part of neomycin sulfate, 0.2 to 0.3 part of 2-roots alcohol, 0.02 to 0.04 part of vitamin C palmitate and 0.03 to 0.1 part of epsilon-polylysine. The dressing can achieve excellent effects of diminishing inflammation, easing pain and promoting wound healing through synergistic cooperation of all the components.

Description

Technical Field

[0001] This invention belongs to the field of wound care technology, specifically relating to a wound dressing that has anti-inflammatory, analgesic, and wound-healing properties and its preparation method. Background Technology

[0002] Wound dressings, as important auxiliary materials for wound treatment, are widely used in clinical practice and daily life. Traditional wound dressings, such as gauze, while possessing some absorbency and breathability, also have significant drawbacks. Gauze tends to stick to the wound, causing secondary damage during changes and resulting in considerable pain for the patient. Furthermore, its poor moisture retention fails to maintain a moist wound environment, hindering cell migration and proliferation, thus delaying the healing process. In addition, gauze provides a weak barrier function, making it difficult to effectively block external bacteria and increasing the risk of wound infection.

[0003] With the development of technology, new types of wound dressings, such as film dressings, hydrocolloid dressings, and alginate dressings, have gradually emerged. While film dressings offer high transparency for easy wound observation and are waterproof and breathable, they are also highly adhesive, easily causing skin damage during changes, and do not absorb exudate, making them unsuitable for wounds with significant exudate. Hydrocolloid dressings can promote epithelial cell migration and accelerate wound healing, but may cause irritation to some skin types, have limited absorption capacity, are unsuitable for wounds with large amounts of exudate, and are relatively expensive. Alginate dressings can quickly and extensively absorb exudate, playing a role in hemostasis and accelerating healing, but with small amounts of exudate, they can easily dry the wound, requiring two layers of dressing for fixation; improper use can also easily cause maceration of the surrounding skin.

[0004] Existing wound dressings still have many shortcomings in key performance areas such as anti-inflammatory, analgesic, and wound healing promotion. Many dressings are not effective at reducing inflammation, failing to effectively suppress the inflammatory response around the wound, leading to increased redness, swelling, and pain. Regarding analgesia, most dressings lack effective analgesic components or mechanisms, often causing patients to endure significant pain during wound recovery. While some dressings can provide a favorable environment for healing to some extent, the lack of synergistic effects from multiple effective ingredients results in slow healing speed, poor healing quality, and a higher likelihood of scarring. Summary of the Invention

[0005] The main objective of this invention is to address the shortcomings of existing wound dressings in terms of anti-inflammatory and analgesic effects and wound healing promotion by providing a novel wound dressing. Through unique formulation design and preparation methods, this dressing can effectively inhibit wound inflammation, reduce pain, and significantly promote the wound healing process and improve healing quality, thereby meeting the urgent clinical and daily life needs for high-performance wound dressings.

[0006] An anti-inflammatory, analgesic, and wound-healing wound dressing is composed of the following components in parts by weight: 6-10 parts sodium alginate oxide, 7-9 parts hydrazide-modified gelatin, 1-1.5 parts tannic acid, 8-12 parts polyethylene glycol, 0.05-0.1 parts cannabidiol, 0.05-0.1 parts neomycin sulfate, 0.2-0.3 parts 2-carboxylic acid, 0.02-0.04 parts vitamin C palmitate, and 0.03-0.1 parts ε-polylysine.

[0007] A method for preparing the aforementioned anti-inflammatory, analgesic, and wound-healing wound dressing includes the following steps: S301: Add sodium oxidized alginate to deionized water and stir to dissolve at 40-50℃ to obtain a sodium oxidized alginate solution with a mass fraction of 2-3%. S302: Tannic acid, polyethylene glycol, cannabidiol, neomycin sulfate, 2-tannin, vitamin C palmitate, and ε-polylysine are added sequentially to the sodium alginate oxidase solution and stirred evenly at 30-40℃ to obtain a mixed solution; S303: Add hydrazide-modified gelatin to deionized water and stir to dissolve at 35-40℃ to obtain a hydrazide-modified gelatin solution with a mass fraction of 3-4%. S304: Add the mixed solution obtained from S302 to the hydrazide gelatin solution while stirring, and react at 25-30℃ for 2-3 hours to allow the two solutions to fully cross-link and form a uniform gel-like substance. S305: Pour the obtained gel-like substance into a mold, freeze at -20 to -15℃ for 2 to 3 hours, and then freeze-dry at a vacuum of 0.01 to 0.05 MPa and a temperature of -50 to -40℃ for 12 to 24 hours. S306: Sterilize the freeze-dried material by irradiation with gamma rays at a dose of 25-30 kGy.

[0008] Beneficial effects The wound dressing of this invention exhibits superior performance advantages through the synergistic effect of its components. In terms of anti-inflammatory properties, tannic acid, cannabidiol, and ε-polylysine work together to effectively inhibit the inflammatory response around the wound. Tannic acid and cannabidiol alleviate inflammatory symptoms by regulating the release of inflammatory mediators and reducing the infiltration of inflammatory cells. ε-polylysine further reduces the inflammatory response by inhibiting bacterial growth and reducing the stimulation of the wound by bacterial toxins. Experiments have shown that after using the dressing of this invention, the levels of inflammatory factors such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) around the wound are significantly reduced, and the inflammatory response is significantly suppressed.

[0009] In terms of pain relief, cannabidiol and 2-tretinoin play a key role. Cannabidiol regulates nerve conduction and reduces the transmission of pain signals by binding to cannabinoid receptors on the surface of human cells. 2-tretinoin, through its cooling and antipruritic effects, directly relieves discomfort around the wound and reduces pain. Clinical trials have shown that patients using the dressing of this invention have significantly lower pain scores during dressing changes than those using traditional dressings, effectively improving patient comfort.

[0010] In promoting wound healing, components such as oxidized sodium alginate, hydrazide-modified gelatin, tannic acid, and vitamin C palmitate work synergistically. The network structure formed by oxidized sodium alginate and hydrazide-modified gelatin provides a good scaffold for cell growth and migration, promoting the formation of granulation tissue; tannic acid and vitamin C palmitate reduce free radical damage to cells through antioxidant effects, while vitamin C palmitate also promotes collagen synthesis, accelerating wound healing.

[0011] Furthermore, the preparation method of the present invention, by precisely controlling the reaction conditions and process parameters of each component, enables the dressing to form a stable three-dimensional network structure, which not only improves the mechanical properties of the dressing, making it less prone to damage during use, but also achieves slow release of the drug, allowing the active ingredients to continuously act on the wound, further enhancing the anti-inflammatory, analgesic, and wound-healing effects of the dressing. Detailed Implementation

[0012] One embodiment of the present invention provides a wound dressing with anti-inflammatory, analgesic, and wound-healing properties, comprising the following components in parts by weight: 6-10 parts sodium alginate oxide, 7-9 parts hydrazide-modified gelatin, 1-1.5 parts tannic acid, 8-12 parts polyethylene glycol, 0.05-0.1 parts cannabidiol, 0.05-0.1 parts neomycin sulfate, 0.2-0.3 parts 2-carboxylic acid, 0.02-0.04 parts vitamin C palmitate, and 0.03-0.1 parts ε-polylysine. Through this formulation, the components synergistically impart excellent anti-inflammatory, analgesic, and wound-healing properties to the dressing, meeting the diverse needs of wound treatment.

[0013] Among them, sodium alginate oxide exhibits excellent biocompatibility and hemostatic properties. It can undergo a cross-linking reaction with calcium ions in wound exudate to form a gel-like substance. This not only effectively absorbs wound exudate but also provides a moist environment for wound healing, which is conducive to cell migration and proliferation. Hydrated gelatin also possesses excellent biocompatibility. It forms a stable network structure with sodium alginate oxide through a Schiff base reaction, enhancing the mechanical properties of the dressing and facilitating the sustained release of drugs, allowing the dressing's active ingredients to continuously act on the wound.

[0014] Tannic acid is a natural polyphenol compound with powerful antioxidant, antibacterial, and anti-inflammatory properties. It can inhibit bacterial growth by binding to proteins and enzymes on the bacterial surface, disrupting bacterial structure and metabolic function; simultaneously, tannic acid can reduce inflammatory responses and promote wound healing. Polyethylene glycol, as a high-molecular polymer, has excellent hydrophilicity and lubricity. It can adjust the viscosity and flexibility of dressings, making them easier to apply and adhere to wounds, while also promoting the uniform dispersion of other ingredients.

[0015] Cannabidiol (CBD) possesses significant anti-inflammatory and analgesic properties. It can regulate the release of inflammatory mediators by binding to cannabinoid receptors on the surface of human cells, reducing inflammatory responses and thus alleviating pain. Neomycin sulfate is a broad-spectrum antibiotic that inhibits various Gram-positive and Gram-negative bacteria, effectively preventing and controlling wound infections. 2-Citrol has a cooling and antipruritic effect, reducing discomfort around wounds and relieving pain. Vitamin C palmitate is a fat-soluble vitamin C derivative that not only has antioxidant properties but also promotes collagen synthesis, aiding in wound healing. ε-Polylysine is a natural antibacterial agent that inhibits Gram-positive, Gram-negative bacteria, yeasts, and molds, further enhancing the antibacterial properties of dressings.

[0016] In some embodiments, the wound dressing comprises the following components in parts by weight: 7-9 parts sodium alginate oxide, 7.5-8.5 parts hydrazide gelatin, 1.2-1.4 parts tannic acid, 9-11 parts polyethylene glycol, 0.06-0.08 parts cannabidiol, 0.06-0.08 parts neomycin sulfate, 0.22-0.28 parts 2-tsitol, 0.025-0.035 parts vitamin C palmitate, and 0.05-0.08 parts ε-polylysine.

[0017] In some embodiments, the wound dressing comprises the following components in parts by weight: 8 parts sodium alginate oxide, 8 parts hydrazide gelatin, 1.3 parts tannic acid, 10 parts polyethylene glycol, 0.07 parts cannabidiol, 0.07 parts neomycin sulfate, 0.25 parts 2-tsitol, 0.03 parts vitamin C palmitate, and 0.06 parts ε-polylysine.

[0018] In some embodiments, sodium alginate oxidase is prepared by the following method: S101: Dissolving sodium alginate: Dissolve sodium alginate in deionized water and stir to obtain a sodium alginate solution.

[0019] S102: Oxidation reaction: Adjust the pH of the sodium alginate solution to 3.0-4.0 with 1 mol / L dilute hydrochloric acid (this pH range can avoid excessive decomposition of sodium periodate while ensuring oxidation efficiency), then add sodium periodate, with a mass ratio of sodium periodate to sodium alginate of 0.4-0.6:1, continue stirring, and react in the dark for 6-8 hours.

[0020] S103: Termination of reaction and purification: After the reaction is complete, add ethylene glycol to the solution (ethylene glycol can react with excess sodium periodate to terminate the oxidation), and stir for 20-30 minutes; then slowly pour the reaction solution into anhydrous ethanol, with a volume ratio of anhydrous ethanol to reaction solution of 2:1, while stirring (stirring speed of 100-200 rpm). At this time, sodium alginate will precipitate out as flocculent precipitate. Filter, wash the filter residue with anhydrous ethanol, and dry to obtain sodium alginate.

[0021] In some embodiments, hydrazide-modified gelatin is prepared by the following method: S201: Dissolving gelatin: Mix gelatin with deionized water at 35-40℃ and stir to dissolve to obtain a gelatin solution.

[0022] S202: Activation of carboxyl groups and hydrazideation reaction: Adjust the pH of the gelatin solution to 5.0-5.5 with 0.1 mol / L NaOH, then add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide, with a molar ratio of 1:0.6 and a mass ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to gelatin of 0.1-0.13:1. Stir for 20-30 min to activate the carboxyl groups of the gelatin; then add adipic acid dihydrazide, with a mass ratio of 0.2-0.3:1 to gelatin, and continue stirring at 35-40℃ for 4-5 h.

[0023] S203: Dialysis purification: After the reaction is completed, cool the reaction solution to room temperature, pour it into a dialysis bag with a molecular weight cutoff of 8000-14000 Da, tie the bag tightly, and dialyze it in deionized water for a total of 48-50 hours.

[0024] S204: Concentration and drying: The dialyzed solution was transferred to a rotary evaporator and concentrated to 1 / 3 of its original volume at 35-40℃ and a vacuum of 0.08-0.1MPa; the concentrate was then poured into a petri dish and placed in a vacuum drying oven at 35-40℃ for 8-10 hours to obtain a film; the film was then pulverized into powder to obtain hydrazide gelatin.

[0025] Another embodiment of the present invention provides a method for preparing the above-mentioned anti-inflammatory, analgesic, and wound-healing wound dressing, comprising the following steps: S301: Add sodium oxidized alginate to deionized water and stir to dissolve at 40-50℃ to obtain a sodium oxidized alginate solution with a mass fraction of 2-3%.

[0026] S302: Tannic acid, polyethylene glycol, cannabidiol, neomycin sulfate, 2-Citrol, vitamin C palmitate, and ε-polylysine are added sequentially to sodium alginate solution and stirred evenly at 30-40℃ to obtain a mixed solution.

[0027] S303: Add hydrazide-modified gelatin to deionized water and stir to dissolve at 35-40℃ to obtain a hydrazide-modified gelatin solution with a mass fraction of 3-4%.

[0028] S304: Add the mixed solution obtained from S302 to the hydrazide gelatin solution while stirring, and react at 25-30℃ for 2-3 hours to allow the two solutions to fully cross-link and form a uniform gel-like substance.

[0029] S305: Pour the obtained gel-like substance into a mold and freeze it at -20 to 15°C for 2 to 3 hours. Then freeze-dry it at a vacuum of 0.01 to 0.05 MPa and a temperature of -50 to 40°C for 12 to 24 hours.

[0030] S306: Sterilize the freeze-dried material by irradiation with gamma rays at a dose of 25-30 kGy.

[0031] Optionally, the stirring speed in S304 is 100-200 rpm.

[0032] The following are examples and comparative examples.

[0033] (1) Oxidized sodium alginate is prepared by the following method: S101: Dissolving sodium alginate: Dissolve sodium alginate in deionized water and stir to obtain a sodium alginate solution.

[0034] S102: Oxidation reaction: Adjust the pH of the sodium alginate solution to 3.0-4.0 with 1 mol / L dilute hydrochloric acid, then add sodium periodate with a mass ratio of sodium periodate to sodium alginate of 0.5:1, continue stirring, and react in the dark for 7 hours.

[0035] S103: Termination of reaction and purification: After the reaction is completed, ethylene glycol is added to the solution and stirred for 25 min; then the reaction solution is slowly poured into anhydrous ethanol at a volume ratio of 2:1 (anhydrous ethanol to reaction solution), while stirring (stirring speed is 100 rpm). At this time, sodium alginate oxide will precipitate out as flocculent precipitate. After filtration, the filter residue is washed with anhydrous ethanol and dried to obtain sodium alginate oxide.

[0036] (2) Acylhydrazide gelatin is prepared by the following method: S201: Dissolving gelatin: Mix gelatin with deionized water at 35°C and stir to dissolve, obtaining a gelatin solution.

[0037] S202: Activation of carboxyl groups and hydrazideation reaction: The pH of the gelatin solution was adjusted to 5.0 with 0.1 mol / L NaOH, followed by the addition of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide, with a molar ratio of 1:0.6 and a mass ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to gelatin of 0.1:1. The mixture was stirred for 25 min to activate the carboxyl groups of the gelatin. Then, adipic acid dihydrazide was added, with a mass ratio of 0.2:1 to gelatin, and the reaction was continued at 35 °C for 4 h.

[0038] S203: Dialysis purification: After the reaction is completed, the reaction solution is cooled to room temperature, poured into a dialysis bag with a molecular weight cutoff of 8000 Da, the bag is tied tightly, and dialyzed in deionized water for a total of 48 hours.

[0039] S204: Concentration and drying: The dialyzed solution was transferred to a rotary evaporator and concentrated to 1 / 3 of its original volume at 35°C and a vacuum of 0.08 MPa; the concentrate was then poured into a petri dish and placed in a vacuum drying oven and dried at 35°C for 8 hours to obtain a film; the film was pulverized into powder to obtain hydrazide-modified gelatin.

[0040] Example 1 In this embodiment, the wound dressing is composed of the following components in parts by weight: 6 parts sodium alginate oxide, 7 parts hydrazide gelatin, 1 part tannic acid, 8 parts polyethylene glycol, 0.05 parts cannabidiol, 0.05 parts neomycin sulfate, 0.2 parts 2-tsitol, 0.02 parts vitamin C palmitate, and 0.03 parts ε-polylysine.

[0041] The preparation method of wound dressing is as follows: S301: Add sodium oxidized alginate to deionized water and stir to dissolve at 40°C to obtain a sodium oxidized alginate solution with a mass fraction of 2%.

[0042] S302: Tannic acid, polyethylene glycol, cannabidiol, neomycin sulfate, 2-Citrol, vitamin C palmitate, and ε-polylysine are added sequentially to the sodium alginate solution and stirred evenly at 40°C to obtain a mixed solution.

[0043] S303: Add hydrazide-modified gelatin to deionized water and stir to dissolve at 35°C to obtain a 3% (w / w) hydrazide-modified gelatin solution.

[0044] S304: Add the mixed solution obtained from S302 to the hydrazide gelatin solution while stirring, and react at 30°C for 2 hours to allow the two solutions to fully cross-link and form a uniform gel-like substance.

[0045] S305: Pour the obtained gel-like substance into a mold, freeze at -20℃ for 2 hours, and then freeze-dry for 12 hours under a vacuum of 0.02MPa and a temperature of -50℃.

[0046] S306: Sterilize the freeze-dried material by irradiation with gamma rays at a dose of 25 kGy.

[0047] Example 2 Compared with Example 1, the difference is that the wound dressing is composed of the following components in parts by weight: 7 parts sodium alginate oxide, 7.5 parts hydrazide gelatin, 1.2 parts tannic acid, 9 parts polyethylene glycol, 0.06 parts cannabidiol, 0.06 parts neomycin sulfate, 0.22 parts 2-tsitol, 0.025 parts vitamin C palmitate, and 0.05 parts ε-polylysine.

[0048] Example 3 Compared with Example 1, the difference is that the wound dressing is composed of the following components in parts by weight: 8 parts sodium alginate oxide, 8 parts hydrazide gelatin, 1.3 parts tannic acid, 10 parts polyethylene glycol, 0.07 parts cannabidiol, 0.07 parts neomycin sulfate, 0.25 parts 2-tsitol, 0.03 parts vitamin C palmitate, and 0.06 parts ε-polylysine.

[0049] Example 4 Compared with Example 1, the difference is that the wound dressing is composed of the following components in parts by weight: 9 parts sodium alginate oxide, 8.5 parts hydrazide gelatin, 1.4 parts tannic acid, 11 parts polyethylene glycol, 0.08 parts cannabidiol, 0.08 parts neomycin sulfate, 0.28 parts 2-tsitol, 0.035 parts vitamin C palmitate, and 0.08 parts ε-polylysine.

[0050] Example 5 Compared with Example 1, the difference is that the wound dressing is composed of the following components in parts by weight: 10 parts sodium alginate oxide, 9 parts hydrazide gelatin, 1.5 parts tannic acid, 12 parts polyethylene glycol, 0.1 parts cannabidiol, 0.1 parts neomycin sulfate, 0.3 parts 2-tsitol, 0.04 parts vitamin C palmitate, and 0.1 parts ε-polylysine.

[0051] Comparative Example 1 The difference compared to Example 1 is that the components do not contain cannabidiol.

[0052] Comparative Example 2 The difference from Example 1 is that sodium oxidized alginate is replaced with sodium alginate.

[0053] Comparative Example 3 The difference from Example 1 is that the hydrazide gelatin is replaced with gelatin.

[0054] Comparative Example 4 Compared with Example 1, the difference is that the wound dressing is composed of the following components in parts by weight: 4 parts sodium alginate oxide, 12 parts hydrazide gelatin, 0.5 parts tannic acid, 5 parts polyethylene glycol, 0.1 parts cannabidiol, 0.2 parts neomycin sulfate, 0.1 parts 2-tsitol, 0.05 parts vitamin C palmitate, and 0.2 parts ε-polylysine.

[0055] Test case (1) Anti-inflammatory effect A mouse dorsal skin inflammation model was established by randomly dividing 90 healthy Kunming mice into 9 groups of 10 each. A 5% xylene solution was applied to the backs of the mice to induce an inflammatory response.

[0056] The wound dressings used in the examples and comparative examples were applied to the backs of mice.

[0057] Twenty-four hours after treatment, skin tissue from the inflamed areas on the backs of mice was collected, and the levels of the inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were detected using enzyme-linked immunosorbent assay (ELISA). IL-6 and TNF-α are key mediators in the inflammatory response, and changes in their levels directly reflect the anti-inflammatory effect of the dressing. Lower levels indicate more significant suppression of the inflammatory response and better anti-inflammatory performance of the dressing.

[0058] (2) Analgesic effect Healthy adult rats were selected, and a burn model was created using the hot water immersion method. A specific area of ​​skin on the rat's back was immersed in 80°C hot water for 10 seconds, causing superficial second-degree burns. The rats were randomly divided into 9 groups: the example group and the comparative group, with 10 rats in each group. Immediately after the burns, dressings prepared for the example and comparative groups were applied to the burn wounds of the rats. Six hours after treatment, the rats' pain levels were assessed by professionals using the Visual Analogue Scale (VAS) under the same environmental and time conditions. A score of 0 indicated no pain, and a score of 10 indicated severe pain. The average value of each group was taken as the test result for that group.

[0059] (3) Wound healing time From the time the wound is created, observe the wound healing process daily and record the time it takes for the wound to fully heal (the epidermis completely covers the wound). Take the average value of each group as the test result for that group.

[0060] (4) Cytotoxicity Prepare dressing extract (1g sample + 10mL culture medium, extract at 37℃ for 24h).

[0061] Co-cultured with L929 cells for 48 hours, then MTT solution (5 mg / mL) was added, and cultured for another 4 hours.

[0062] Measure the absorbance at 570 nm and calculate the cell viability: (sample group absorbance / blank group absorbance) × 100%. Take the average value of each group as the test result for that group.

[0063] The test results are shown in the table below.

[0064]

[0065] The results above show that the wound dressing of the present invention has excellent anti-inflammatory, analgesic, and wound-healing effects.

[0066] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

[0067] For those skilled in the art, based on the ideas of this invention, there will be changes in the specific implementation methods and application scope. Therefore, the content of this specification should not be construed as a limitation of this invention.

Claims

1. An anti-inflammatory analgesic wound dressing to promote wound healing, characterized in that, consists of the following components in mass parts: 6-10 parts of oxidized sodium alginate, 7-9 parts of hydrazidated gelatin, 1-1.5 parts of tannic acid, 8-12 parts of polyethylene glycol, 0.05-0.1 parts of cannabidiol, 0.05-0.1 parts of neomycin sulfate, 0.2-0.3 parts of 2-ethylhexanol, 0.02-0.04 parts of vitamin C palmitate, 0.03-0.1 parts of ε-polylysine.

2. The anti-inflammatory analgesic wound-healing-promoting wound dressing as claimed in claim 1, wherein, consists of the following components in mass parts: 7-9 parts of oxidized sodium alginate, 7.5-8.5 parts of hydrazidated gelatin, 1.2-1.4 parts of tannic acid, 9-11 parts of polyethylene glycol, 0.06-0.08 parts of cannabidiol, 0.06-0.08 parts of neomycin sulfate, 0.22-0.28 parts of 2-ethylhexanol, 0.025-0.035 parts of vitamin C palmitate, 0.05-0.08 parts of ε-polylysine.

3. The anti-inflammatory analgesic wound-healing-promoting wound dressing as claimed in claim 2, wherein, consists of the following components in mass parts: 8 parts of oxidized sodium alginate, 8 parts of hydrazidated gelatin, 1.3 parts of tannic acid, 10 parts of polyethylene glycol, 0.07 parts of cannabidiol, 0.07 parts of neomycin sulfate, 0.25 parts of 2-ethylhexanol, 0.03 parts of vitamin C palmitate, 0.06 parts of ε-polylysine.

4. The anti-inflammatory analgesic wound dressing for promoting wound healing according to any one of claims 1-3, wherein the oxidized sodium alginate is prepared by the following method: S101: dissolving sodium alginate: sodium alginate is dissolved in deionized water, stirred and dissolved to obtain a sodium alginate solution; S102: oxidation reaction: the pH of the sodium alginate solution is adjusted to 3.0-4.0 with 1 mol / L dilute hydrochloric acid, then sodium periodate is added, the mass ratio of sodium periodate to sodium alginate is 0.4-0.6:1, continue to stir and react in the dark for 6-8 h; S103: terminating reaction and purification: after the reaction is completed, ethylene glycol is added to the solution and stirred for 20-30 min; then the reaction solution is slowly poured into anhydrous ethanol, the volume ratio of anhydrous ethanol to reaction solution is 2:1, stirring while pouring, at this time the oxidized sodium alginate will precipitate in the form of a flocculent precipitate, which is filtered, the filter residue is washed with anhydrous ethanol and dried to obtain the oxidized sodium alginate.

5. The anti-inflammatory analgesic wound dressing for promoting wound healing according to any one of claims 1-3, wherein the hydrazidated gelatin is prepared by the following method: S201: dissolving gelatin: gelatin is mixed with deionized water at 35-40℃, stirred and dissolved to obtain a gelatin solution; S202: Carboxyl activation and hydrazide reaction: adjust the pH of the gelatin solution to 5.0-5.5 with 0.1 mol / L NaOH, then add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide, the molar ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to N-hydroxysuccinimide is 1:0.6, the mass ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to gelatin is 0.1-0.13:1, and stir for 20-30 min to activate the carboxyl group of the gelatin; then add adipic acid dihydrazide, the mass ratio of adipic acid dihydrazide to gelatin is 0.2-0.3:1, and continue to stir at 35-40℃ for 4-5 h; S203: Dialysis purification: after the reaction is completed, cool the reaction solution to room temperature, pour it into a dialysis bag with a molecular weight cutoff of 8000-14000 Da, tighten the bag opening, and dialyze in deionized water for a total of 48-50 h; S204: Concentration and drying: transfer the dialyzed solution to a rotary evaporator, concentrate to 1 / 3 of the original volume under the conditions of 35-40℃ and vacuum degree 0.08-0.1 MPa; then pour the concentrated solution into a culture dish and place it in a vacuum drying oven at 35-40℃ for 8-10 h to obtain a thin film; crush the thin film into powder to obtain hydrazide gelatin.

6. A method of preparing an anti-inflammatory analgesic wound-healing promoting wound dressing according to any one of claims 1 to 5, characterized in that, Comprising the following steps: S301: Add oxidized sodium alginate to deionized water and stir to dissolve at 40-50℃ to obtain a 2-3% mass fraction of oxidized sodium alginate solution; S302: Add tannic acid, polyethylene glycol, cannabidiol, neomycin sulfate, 2-propanol, vitamin C palmitate, and ε-polylysine to the oxidized sodium alginate solution in sequence and stir to mix at 30-40℃ to obtain a mixed solution; S303: Add hydrazide gelatin to deionized water and stir to dissolve at 35-40℃ to obtain a 3-4% mass fraction of hydrazide gelatin solution; S304: Add the mixed solution obtained in S302 to the hydrazide gelatin solution and stir while adding, and react at 25-30℃ for 2-3 h to allow the two solutions to crosslink fully and form a uniform gel-like material; S305: Pour the obtained gel-like material into a mold, freeze at -20--15℃ for 2-3 h, and then freeze-dry at a vacuum degree of 0.01-0.05 MPa and a temperature of -50--40℃ for 12-24 h; S306: Sterilize the freeze-dried material with γ-ray irradiation at a dose of 25-30 kGy.

7. The method of claim 6, wherein the anti-inflammatory analgesic wound-healing-promoting wound dressing is prepared by the steps of: (a) mixing the anti-inflammatory analgesic agent with the base material; (b) applying the mixture to a wound; and (c) allowing the mixture to dry. The stirring speed in S304 is 100-200 rpm.

Images